EUCAST technical note on anidulafungin

被引：47

作者：

Arendrup, M. C. ^{[1
]}

Rodriguez-Tudela, J-L ^{[2
]}

Lass-Floerl, C. ^{[3
]}

Cuenca-Estrella, M. ^{[2
]}

Donnelly, J. P. ^{[4
,5
]}

Hope, W. ^{[6
]}

机构：

[1] Statens Serum Inst, Dept Microbiol Surveillance & Res, Unit Mycol, DK-2300 Copenhagen, Denmark

[2] Inst Salud Carlos III, Mycol Reference Lab, Natl Ctr Microbiol, Majadahonda, Spain

[3] Innsbruck Med Univ, Div Hyg & Microbiol, Innsbruck, Austria

[4] Radboud Univ Nijmegen, Dept Haematol, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[5] Radboud Univ Nijmegen, Nijmegen Univ Ctr Infect Dis, NL-6525 ED Nijmegen, Netherlands

[6] Univ Manchester, Manchester, Lancs, England

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2011年 / 17卷 / 11期

关键词：

Anidulafungin; breakpoints; EUCAST Technical Note; susceptibility testing; CANDIDA-ALBICANS; INVASIVE CANDIDIASIS; FLUCONAZOLE; MUTATIONS;

D O I：

10.1111/j.1469-0691.2011.03647.x

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available at: http://www.eucast.org). Species-specific breakpoints for C. albicans are S <= 0.03 mg/L and R >0.03 mg/L and for C. glabrata, C. tropicalis and C. krusei S <= 0.06 mg/L and R >0.06 mg/L. C. parapsilosis was not regarded a good target for anidulafungin. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical experience. Breakpoints will be reviewed regularly.

引用

页码：E18 / E20

页数：3

共 15 条

[1]

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media [J].

Arendrup, Maiken Cavling ;

Garcia-Effron, Guillermo ;

Lass-Floerl, Cornelia ;

Gomez Lopez, Alicia ;

Rodriguez-Tudela, Juan-Luis ;

Cuenca-Estrella, Manuel ;

Perlin, David S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :426-439

[2]

Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing [J].

Arendrup, Maiken Cavling ;

Garcia-Effron, Guillermo ;

Buzina, Walter ;

Mortensen, Klaus Leth ;

Reiter, Nanna ;

Lundin, Christian ;

Jensen, Henrik Elvang ;

Lass-Florl, Cornelia ;

Perlin, David S. ;

Bruun, Brita .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1185-1193

[3]

Acquired resistance to echinocandins in Candida albicans:: case report and review [J].

Baixench, Marie-Therese ;

Aoun, Naji ;

Desnos-Ollivier, Marie ;

Garcia-Hermoso, Dea ;

Bretagne, Stephane ;

Ramires, Sandrine ;

Piketty, Christophe ;

Dannaoui, Eric .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (06) :1076-1083

[4]

In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin [J].

Damle, Bharat D. ;

Dowell, James A. ;

Walsky, Robert L. ;

Weber, Gregory L. ;

Stogniew, Martin ;

Inskeep, Philip B. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1149-1156

[5]

DANNAOUI E, 2010, CLIN MICROBIOL INFEC, V16, pS77

[6]

Mutations in the fks1 gene in Candida albicans, C-tropicalis, and C-krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing [J].

Desnos-Ollivier, Marie ;

Bretagne, Stephane ;

Raoux, Dorothee ;

Hoinard, Damien ;

Dromer, Francoise ;

Dannaoui, Eric .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3092-3098

[7]

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal [J].

Dowell, JA ;

Knebel, W ;

Ludden, T ;

Stogniew, M ;

Krause, D ;

Henkel, T .

JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (06) :590-598

[8]

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint [J].

Garcia-Effron, Guillermo ;

Lee, Samuel ;

Park, Steven ;

Cleary, John D. ;

Perlin, David S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) :3690-3699

[9]

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints [J].

Garcia-Effron, Guillermo ;

Park, Steven ;

Perlin, David S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) :112-122

[10]

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis [J].

Krause, DS ;

Simjee, AE ;

van Rensburg, C ;

Viljoen, J ;

Walsh, TJ ;

Goldstein, BP ;

Wible, M ;

Henkel, T .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :770-775

← 1 2 →